These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 1600683)

  • 21. Unapproved uses of approved drugs: the physician, the package insert, and the Food and Drug Administration: subject review. American Academy of Pediatrics Committee on Drugs.
    Pediatrics; 1996 Jul; 98(1):143-5. PubMed ID: 8668390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stoning a dead bird: advertising limits on approved new drugs.
    Strobos J
    Food Drug Law J; 1995; 50(4):533-51. PubMed ID: 10343018
    [No Abstract]   [Full Text] [Related]  

  • 23. Involuntary self-intoxication with triazolam.
    Denson R
    Psychiatr J Univ Ott; 1987 Nov; 12(4):242-3. PubMed ID: 3326011
    [No Abstract]   [Full Text] [Related]  

  • 24. Proposed NSAID package insert labeling.
    Food and Drug Administration U.S. Public Health Service
    J Pain Palliat Care Pharmacother; 2006; 20(1):49-55. PubMed ID: 16687359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. History of FDA patient package insert requirements.
    Am J Hosp Pharm; 1980 Dec; 37(12):1660-1. PubMed ID: 7004180
    [No Abstract]   [Full Text] [Related]  

  • 26. Safety-related drug labeling changes approved by FDA.
    White GG
    J Toxicol Clin Toxicol; 1998; 36(3):265-7. PubMed ID: 9678979
    [No Abstract]   [Full Text] [Related]  

  • 27. Feasibility of an every-other-night regimen in insomniac patients: subjective hypnotic effectiveness of quazepam, triazolam, and placebo.
    Scharf MB
    J Clin Psychiatry; 1993 Jan; 54(1):33-8. PubMed ID: 8428895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Over-the-counter human drugs; labeling requirements. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 Mar; 64(51):13254-303. PubMed ID: 10557606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug safety labeling for doctors.
    Hecht A
    FDA Consum; 1979 Oct; 13(8):12-3. PubMed ID: 10309108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prescription drugs; revocation of final guideline patient package inserts and withdrawal of draft guideline patient package inserts--Food and Drug Administration. Notice.
    Fed Regist; 1982 Sep; 47(173):39249-50. PubMed ID: 10258155
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recommendations for the labeling of large volume parenterals. National Coordinating Committee on Large Volume Parenterals.
    Am J Hosp Pharm; 1978 Jan; 35(1):49-51. PubMed ID: 623118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The new Food and Drug Administration drug package insert: implications for patient safety and clinical care.
    Watson KT; Barash PG
    Anesth Analg; 2009 Jan; 108(1):211-8. PubMed ID: 19095852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PDA response. FDA advance notice of proposed rulemaking on electronic identification/signatures. Parenteral Drug Association.
    J Parenter Sci Technol; 1993; 47(1):4-8. PubMed ID: 8445499
    [No Abstract]   [Full Text] [Related]  

  • 34. Food and Drug Administration--Prescription drug products; patient package inserts requirements. Final rule.
    Fed Regist; 1980 Sep; 45(179 Pt 2):60754-84. PubMed ID: 10248285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of zopiclone and triazolam in the treatment of geriatric insomniacs.
    Elie R; Frenay M; Le Morvan P; Bourgouin J
    Int Clin Psychopharmacol; 1990 Apr; 5 Suppl 2():39-46. PubMed ID: 2201729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FDA transparency rules could hit small companies hardest.
    Allison M
    Nat Biotechnol; 2010 Aug; 28(8):767-8. PubMed ID: 20697386
    [No Abstract]   [Full Text] [Related]  

  • 37. Prescription drug products; patient labeling requirements: proposed rule.
    Fed Regist; 1979 Jul; 44(131 Pt 2):40015-41. PubMed ID: 10242793
    [No Abstract]   [Full Text] [Related]  

  • 38. FDA-approved drugs to treat sleep disorders.
    J Psychosoc Nurs Ment Health Serv; 2014 Oct; 52(10):21-2. PubMed ID: 25291724
    [No Abstract]   [Full Text] [Related]  

  • 39. [Between the two...].
    Labrecque G
    Union Med Can; 1980 Oct; 109(10):1468-70. PubMed ID: 7466970
    [No Abstract]   [Full Text] [Related]  

  • 40. FDA prohibits extralabel use of two drug classes.
    J Am Vet Med Assoc; 1997 Aug; 211(3):269. PubMed ID: 9262656
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.